Rafael Fonseca MDChief Innovation Officer, Mayo Clinic; Getz Family Professor of Cancer, Mayo Clinic School of Medicine, Phoenix, Arizona
Rafael Fonseca, MD, is the Getz Family Professor of cancer and a Professor of Medicine. He is a consultant in the Division of Hematology/Oncology at the Mayo Clinic, in Arizona and Chief Innovation Officer Dr. Fonseca earned his MD at Universidad Anahuac, Mexico. He completed a residency in internal medicine at the University of Miami, FL, and a fellowship in hematology and medical oncology at Mayo Graduate School of Medicine, Rochester, MN. He is a clinical investigator for the Damon Runyon Cancer Research Fund.
Dr. Fonseca's practice has focused on the diagnosis and treatment of plasma cell disorders and leading the multiple myeloma team in its effort to develop a better understanding of the disease and its impact on patients. In his laboratory, Dr. Fonseca has led his team of researchers in concentrating on the genetic nature of the clonal cells of plasma cell disorders, myeloma bone disease, prognostic markers and development of new therapies for the disease.
Throughout his training and career, Dr. Fonseca has received numerous awards and honors, including the Young Investigator Award in Hematology (Celgene – Achievement Awards for Clinical Research in Hematology), Damon Runyon-Walter Winchell Clinical Investigator Award, and the International Waldenström Macroglobulinemia Research Award. Most notably he is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. Dr. Fonseca holds memberships and serves in positions for organizations such as the American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, and the International Myeloma Society. Dr. Fonseca has an adjunct academic appointment at the Translational Genomics Research Institute (TGen). His research has been funded by the National Cancer Institute (R01, P01, SPORE), the Leukemia and Lymphoma Society, the Multiple Myeloma Research Fund, and the Damon Runyon Cancer Research Fund.
Dr. Fonseca serves as reviewer and in editorial capacities for medical publications including among others Blood, Lancet, Nature Medicine, Cancer Cell, Leukemia, and the New England Journal of Medicine, among others. He has given many national and international presentations as a visiting professor, and has authored numerous articles (over 300), book chapters, editorials, and abstracts.
Dr. Fonseca is a consultant for Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Merck, Juno, Kite, Aduro, OncoTracker, Oncopeptides, GSK, AbbVie.
He is on the Scientific Advisory Board for Adaptive Biotechnologies and OncoTracker.
Mayo Clinic holds the patent in Dr. Fonseca's name, for which he receives about $2000 in revenue per year.
Recent Contributions to PracticeUpdate:
- Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone as Induction Therapy for High-Risk Transplant-Eligible Patients With Multiple Myeloma
- Novel Therapies for Multiple Myeloma
- Carfilzomib, Lenalidomide, and Dexamethasone After Stem Cell Transplant for Multiple Myeloma
- Lenalidomide, Bortezomib, and Dexamethasone With or Without Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
- Minimal Residual Disease and Survival Outcomes in Patients With Multiple Myeloma After ASCT and Maintenance With Lenalidomide
- Long-Term Follow-Up of Combination of Anti–B-Cell Maturation Antigen and Anti–CD19 CAR T Cells in Multiple Myeloma
- Blinatumomab Maintenance After Allogeneic HCT for B-ALL
- Isatuximab + Pomalidomide + Dexamethasone vs Pomalidomide + Dexamethasone for Relapsed and Refractory Multiple Myeloma
- Attrition Rate and Economic Burden of Multiple Myeloma Progression